KR20020063180A - 물질 탐닉 치료방법 - Google Patents

물질 탐닉 치료방법 Download PDF

Info

Publication number
KR20020063180A
KR20020063180A KR1020027005864A KR20027005864A KR20020063180A KR 20020063180 A KR20020063180 A KR 20020063180A KR 1020027005864 A KR1020027005864 A KR 1020027005864A KR 20027005864 A KR20027005864 A KR 20027005864A KR 20020063180 A KR20020063180 A KR 20020063180A
Authority
KR
South Korea
Prior art keywords
calcium channel
amlodipine
verapamil
sustained release
nifedipine
Prior art date
Application number
KR1020027005864A
Other languages
English (en)
Korean (ko)
Inventor
알버트 슐만
Original Assignee
알버트 슐만
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926218.0A external-priority patent/GB9926218D0/en
Priority claimed from GBGB9929595.8A external-priority patent/GB9929595D0/en
Application filed by 알버트 슐만 filed Critical 알버트 슐만
Publication of KR20020063180A publication Critical patent/KR20020063180A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027005864A 1999-11-06 2000-11-06 물질 탐닉 치료방법 KR20020063180A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9926218.0 1999-11-06
GBGB9926218.0A GB9926218D0 (en) 1999-11-06 1999-11-06 Composition and method for the treatment of drug abuse
GBGB9929595.8A GB9929595D0 (en) 1999-12-16 1999-12-16 New composition and method for the treatment of drug abuse
GB9929595.8 1999-12-16
PCT/AU2000/001367 WO2001034161A1 (fr) 1999-11-06 2000-11-06 Procede de traitement de l'accoutumance aux substances intoxiquantes

Publications (1)

Publication Number Publication Date
KR20020063180A true KR20020063180A (ko) 2002-08-01

Family

ID=26316056

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027005864A KR20020063180A (ko) 1999-11-06 2000-11-06 물질 탐닉 치료방법

Country Status (9)

Country Link
EP (1) EP1242093A1 (fr)
JP (1) JP2004508274A (fr)
KR (1) KR20020063180A (fr)
CN (1) CN1402638A (fr)
AU (1) AU1256501A (fr)
CA (1) CA2390101A1 (fr)
NO (1) NO20022157L (fr)
NZ (1) NZ518992A (fr)
WO (1) WO2001034161A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2010141712A2 (fr) * 2009-06-03 2010-12-09 Marquette University Modulation de l'activité du canal de potassium de kcnq dans le traitement de troubles psychiatriques et de symptômes afférents
WO2021072213A1 (fr) * 2019-10-11 2021-04-15 The Trustees Of Indiana University Prégabaline pour le traitement d'un trouble lié à l'utilisation des opioïdes

Also Published As

Publication number Publication date
AU1256501A (en) 2001-06-06
EP1242093A1 (fr) 2002-09-25
CN1402638A (zh) 2003-03-12
NO20022157L (no) 2002-07-04
JP2004508274A (ja) 2004-03-18
WO2001034161A1 (fr) 2001-05-17
NZ518992A (en) 2004-02-27
CA2390101A1 (fr) 2001-05-17
NO20022157D0 (no) 2002-05-06

Similar Documents

Publication Publication Date Title
US8426439B2 (en) Compositions and methods for prophylaxis and treatment of addictions
US6071918A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US20040024006A1 (en) Opioid pharmaceutical compositions
WO2001052851A1 (fr) Methodes de traitement d'abus de substances
WO2000021515A9 (fr) Codeine intra-nasale permettant d'eliminer rapidement la toux et de soulager rapidement la douleur
KR101767273B1 (ko) 중독의 예방 및 치료용 조성물 및 방법
KR20020081271A (ko) 물질 남용의 치료 방법
AU2002323873B2 (en) Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism
JPS6342605B2 (fr)
MXPA02003670A (es) Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
JP7244992B2 (ja) オピオイドとｎ－アシルエタノールアミンの組み合わせ
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
KR20020063180A (ko) 물질 탐닉 치료방법
WO2011109743A2 (fr) Effets synergiques d'associations de buprenorphine et d'opioïdes pour le traitement des douleurs
CN111479592A (zh) 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗
US20190022077A1 (en) Compositions and methods for prophylaxis and treatment of addictions
AU2001226574A1 (en) Methods for the treatment of substance abuse
EP1250136A1 (fr) Methodes de traitement d'abus de substances
JP2009510158A (ja) 毒物依存症の治療におけるネボグラミンの使用

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid